Canfield Scientific has commercially launched a version of its whole body, 3D imaging system, the Vectra WB360. It announced the launch during the 75th annual Meeting of the American Academy of Dermatology in Orlando, Fla.
The Vectra WB360 imaging system is able to capture the entire exposed skin surface with 46 stereo vision pods and is able to produce a single high-resolution 3D image. It has been proven to be one of the most advanced solutions for skin cancer screenings after having undergone various use at 4 skin cancer centers over the last 3 years.
It has also been used for viewing other skin conditions like psoriasis, vitiligo, CTCL, neurofibromatosis and burn management, lymphedema management and plastic reconstructive surgery.
The imaging system uses a combination of polarized and non-polarized lighting while the Canfield-designed custom lighting modules use xenon flash technology that has been modified to capture images on the skin surface. It creates front-of-the-body and back-of-the-body images to give a full body visualization for clinical review in less than a second. This helps eliminate the need for skilled medical photographers in patient photography.
The Vectra WB360 uses a DermaGraphix Body Mapping Solution that helps create the unique and high-resolution 3D body images. It has a powerfully designed dashboard that gives a complete view of the patient’s photographic history and has wireless lesion tagging with the VEOS DS3 dermatoscope, linking images of lesions to the 3D body map for easier exams and follow-ups.
DermaGraphix Tracker is able to identify new or changing lesions between doctor visits which ensures that would-be probable lesions are caught in their most treatable stages.
“We believe the Vectra WB360 will revolutionize how physicians monitor high-risk patients,” said founder and president of Canfield Scientific Doug Canfield in a press release. “Our technology can help improve and even save lives.”
The Vectra WB360 is available worldwide and can be found through Canfield Scientific.
[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]